Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
- Details
- Category: Novartis
Novartis announced today that it will further expand its long-standing partnership with Medicines for Malaria Venture (MMV). Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from MMV in collaboration with the Bill & Melinda Gates Foundation.
Merck in agreement with HAPPYneuron to offer first-of-its kind e-Health solution for people living with multiple sclerosis
- Details
- Category: Merck Group
Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in which Merck will receive an exclusive license to the company's cognitive remediation training program for people living with multiple sclerosis (MS).
Merck Accelerator expands its reach to Silicon Valley
- Details
- Category: Merck Group
Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Nairobi, Kenya. Globally, Merck is seeking young start-ups in the fields of healthcare, life science and performance materials with a focus on digital solutions.
AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio
- Details
- Category: AstraZeneca
AstraZeneca today announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest).
Bayer Science & Education Foundation launches new round of funding
- Details
- Category: Bayer
Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambitious students can apply for an Otto Bayer, Carl Duisberg, Jeff Schell, or Kurt Hansen scholarship if they are aiming to undertake a study project abroad or from foreign countries planning a project in Germany.
Boehringer Ingelheim and Harvard scientists establish a research alliance
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) and nonalcoholic steatohepatitis (NASH).
Merck announces survey results exploring biopharma industry's evolving risk model
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape. The survey, sponsored by Merck, was conducted by the Economist Intelligence Unit (EIU), a leading resource for economic and business research, forecasting and analysis.
More Pharma News ...
- Pfizer presents promising data from next generation ALK/ROS1 inhibitor in advanced non-small cell lung cancer
- AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America
- Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS
- Novartis highlights its strong foundation for long-term, sustainable growth
- Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
- AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016
- Merck and Pfizer to present Avelumab data in seven different cancers at ASCO annual meeting